These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 34502413)
21. Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits. Spijker HS; Song H; Ellenbroek JH; Roefs MM; Engelse MA; Bos E; Koster AJ; Rabelink TJ; Hansen BC; Clark A; Carlotti F; de Koning EJ Diabetes; 2015 Aug; 64(8):2928-38. PubMed ID: 25918235 [TBL] [Abstract][Full Text] [Related]
22. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Yamagishi S; Matsui T Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436 [TBL] [Abstract][Full Text] [Related]
23. Pancreatic α-cells - The unsung heroes in islet function. Wendt A; Eliasson L Semin Cell Dev Biol; 2020 Jul; 103():41-50. PubMed ID: 31983511 [TBL] [Abstract][Full Text] [Related]
24. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY. Guida C; McCulloch LJ; Godazgar M; Stephen SD; Baker C; Basco D; Dong J; Chen D; Clark A; Ramracheya RD Diabetes Obes Metab; 2018 Mar; 20(3):571-581. PubMed ID: 28892258 [TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. van Genugten RE; van Raalte DH; Diamant M Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172 [TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Guyton J; Jeon M; Brooks A Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934 [TBL] [Abstract][Full Text] [Related]
27. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Garber AJ Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667 [TBL] [Abstract][Full Text] [Related]
28. Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Fiori JL; Shin YK; Kim W; Krzysik-Walker SM; González-Mariscal I; Carlson OD; Sanghvi M; Moaddel R; Farhang K; Gadkaree SK; Doyle ME; Pearson KJ; Mattison JA; de Cabo R; Egan JM Diabetes; 2013 Oct; 62(10):3500-13. PubMed ID: 23884882 [TBL] [Abstract][Full Text] [Related]
29. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079 [TBL] [Abstract][Full Text] [Related]
30. [Significance of the regulation of hyperglucagonemia in type 2 diabetes mellitus]. Miuchi M; Miyagawa J; Namba M Nihon Rinsho; 2015 Dec; 73(12):1988-94. PubMed ID: 26666142 [TBL] [Abstract][Full Text] [Related]
32. Growth factor signalling in the regulation of α-cell fate. Kawamori D; Akiyama M; Hu J; Hambro B; Kulkarni RN Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():21-30. PubMed ID: 21824253 [TBL] [Abstract][Full Text] [Related]
33. Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances function of human islets. Wang MY; Dean ED; Quittner-Strom E; Zhu Y; Chowdhury KH; Zhang Z; Zhao S; Li N; Ye R; Lee Y; Zhang Y; Chen S; Yu X; Leonard DC; Poffenberger G; Von Deylen A; McCorkle SK; Schlegel A; Sloop KW; Efanov AM; Gimeno RE; Scherer PE; Powers AC; Unger RH; Holland WL Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619103 [TBL] [Abstract][Full Text] [Related]
34. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107 [TBL] [Abstract][Full Text] [Related]
35. Incretins: their physiology and application in the treatment of diabetes mellitus. Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141 [TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Hemmingsen B; Sonne DP; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279 [TBL] [Abstract][Full Text] [Related]
37. Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy. Horie I; Haraguchi A; Sako A; Akeshima J; Niri T; Shigeno R; Ito A; Nozaki A; Natsuda S; Akazawa S; Mori Y; Ando T; Kawakami A; Abiru N Diabetes Res Clin Pract; 2018 Oct; 144():161-170. PubMed ID: 30194951 [TBL] [Abstract][Full Text] [Related]